Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
Study to Evaluate Home Vision Testing in Participants Who Receive Ranibizumab (Lucentis®)
- Conditions
- Macular EdemaMacular Degeneration
- Interventions
- Other: Ranibizumab
- First Posted Date
- 2015-04-17
- Last Posted Date
- 2019-06-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 47
- Registration Number
- NCT02420132
- Locations
- 🇺🇸
Rocky Mountain Retina, Salt Lake City, Utah, United States
Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2015-04-17
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 110
- Registration Number
- NCT02419742
- Locations
- 🇮🇳
Jehangir Clinical Development Centre Pvt. Ltd; Cancer Research Room, Pune, Maharashtra, India
🇮🇳Manipal Hospital; Department of Oncology, Bangalore, Karnataka, India
🇮🇳MAX Balaji Hospital, Delhi, India
A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2015-04-06
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 8
- Registration Number
- NCT02409355
- Locations
- 🇺🇸
University of Maryland, Baltimore, Maryland, United States
🇺🇸California Cancer Associates for Research & Excellence, Inc., Encinitas, California, United States
🇺🇸Marin Cancer Care Inc, Greenbrae, California, United States
A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2015-04-06
- Last Posted Date
- 2023-03-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 572
- Registration Number
- NCT02409342
- Locations
- 🇫🇷
Centre D'oncologie de Gentilly, Nancy, France
🇫🇷Centre Hospitalier Regional Sud Reunion, Saint-pierre, France
🇧🇷Centro de Pesquisas Clinicas em Oncologia - CPCO, Cachoeiro de Itapemirim, ES, Brazil
Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A
- Conditions
- Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2015-04-02
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 139
- Registration Number
- NCT02406092
- Locations
- 🇲🇦
Hôpital d'enfants de Rabat - Service d'hémato-oncologie pédiatrique, Rabat, Morocco
🇩🇿Hôpital Dorban CHU Annaba, Service d'Hématologie, Annaba, Algeria
🇩🇿Centre hospitalo-univerisitaire de Tizi Ouzou - Nedir Mohamed;Service d'hématologie, Tizi Ouzou, Algeria
Comparing Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections to Reach HbA1c Targets in Children and Adolescents With Type 1 Diabetes
- Conditions
- Diabetes Mellitus Type 1
- Interventions
- Device: Accu-Chek Insight Pump System
- First Posted Date
- 2015-03-31
- Last Posted Date
- 2017-11-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 43
- Registration Number
- NCT02403375
- Locations
- 🇦🇹
Medical University Graz, Graz, Austria
🇩🇪Kinderkrankenhaus auf der Bult, Hannover, Germany
🇦🇹Medical University of Vienna-Dept of Pediatrics, Vienna, Austria
Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144
- First Posted Date
- 2015-03-31
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 790
- Registration Number
- NCT02403323
- Locations
- 🇭🇺
Semmelweis Egyetem; Belgyogyaszati es Hematologiai Klinika, Budapest, Hungary
🇺🇸Valley Gastroenterology Consultants, Arcadia, California, United States
🇺🇸University of California San Diego Medical Center, La Jolla, California, United States
Non-Interventional Study of Tocilizumab Subcutaneous (SC) Monotherapy in Participants With Rheumatoid Arthritis (RA)
- First Posted Date
- 2015-03-30
- Last Posted Date
- 2019-12-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 353
- Registration Number
- NCT02402686
- Locations
- 🇭🇺
National Institute of Rheumatology and Physiotherapy; 4Th Rheumatology Department, Budapest, Hungary
🇭🇺Budai Irgalmasrendi Kórház KHT. II. Reumatológia, Budapest, Hungary
🇭🇺Szent Andras Reumakorhaz; Reumatologia, Heviz, Hungary
Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2015-03-30
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 418
- Registration Number
- NCT02402712
- Locations
- 🇵🇱
MAGODENT Sp. z o.o., Warsaw, Poland
🇫🇷Pole Sante Republique; Pharmacie Oncologique, Clermont Ferrand, France
🇩🇪Studienzentrum Aschaffenburg, Aschaffenburg, Germany
A Study of Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
- Conditions
- Geographic Atrophy
- Interventions
- Other: No intervention
- First Posted Date
- 2015-03-26
- Last Posted Date
- 2019-08-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 202
- Registration Number
- NCT02399072
- Locations
- 🇺🇸
Midwest Vision Research Foundation, Chesterfield, Missouri, United States
🇺🇸Retina Consultants of Houston, The Woodlands, Texas, United States
🇺🇸Retina Assoc of Cleveland Inc, Cleveland, Ohio, United States